Achromatopsia – Epidemiology – Mature Markets Data
DRG Epidemiology’s coverage of achromatopsia (ACHM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of ACHM for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s ACHM forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACHM over the forecast period?
How many cases of ACHM are due to specific genetic mutations?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following:
Diagnosed prevalent cases of ACHM by mutation status.
Achromatopsia - Epidemiology - Mature Markets Data
Introduction
Key Findings
Diagnosed Prevalence of Achromatopsia per 100,000 People of All Ages in 2019 and 2029
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Achromatopsia over the Next Ten Years
Analysis of the Diagnosed Prevalent Cases of Achromatopsia in 2019 by Mutation Status
Epidemiology Data
Methods
Diagnosed Prevalent Cases of Achromatopsia
Diagnosed Prevalent Cases of Achromatopsia by Mutation Status
Reference Materials
Literature Review
Studies Included in the Analysis of Achromatopsia
Studies Excluded from the Analysis of Achromatopsia
Risk/Protective Factors
Risk/Protective Factors for Achromatopsia
Bibliography
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.
Nicole Zhang, M.P.H.
Nicole Zhang, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she worked as a research analyst at Massachusetts General Hospital, where she independently managed data from a food information survey conducted in Chelsea, Massachusetts. She has also worked for the Massachusetts Department of Public Health, conducting secondary research in the field of gestational diabetes. She holds an M.P.H. from Tufts Medical School, where she specialized in epidemiology and biostatistics. She also holds a B.A. in chemistry and statistics from Mount Holyoke College.
